Molecular Partners AG (MOLN):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C7548)
◆英語タイトル:Molecular Partners AG (MOLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7548
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:41
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Molecular Partners AG (Molecular Partners) is a clinical stage biopharmaceutical company that provides biological drugs. The company provides advanced pipeline products such as abicipar, a designed ankyrin repeat protein based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration. It develops drugs on DARPin base technology and other product candidates. Molecular Partners develops products for ophthalmic conditions, cancer, immune disorders and other indications. The company also provides clinical trial services and small protein therapies called Darpin therapeutics. It has partnership with pharmaceutical company to strengthen drug platforms through in-house development, licensing, collaboration, and others. Molecular Partners is headquartered in Zurich, Switzerland.

Molecular Partners AG (MOLN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Molecular Partners AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Molecular Partners AG, Medical Devices Deals, 2012 to YTD 2018 9
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Molecular Partners AG, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Molecular Partners and AstraZeneca Enter into Partnership 11
Molecular Partners Reinforces Partnership with Allergan 12
Allergan Exercises Option Agreement with Molecular Partners 13
Equity Offering 14
Molecular Partners Raises USD31.7 Million in Private Placement of Shares 14
Molecular Partners Announces Partial Exercise of Underwriter’s Option for IPO for USD108 Million 15
Molecular Partners AG – Key Competitors 17
Molecular Partners AG – Key Employees 18
Molecular Partners AG – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Financial Announcements 20
Aug 30, 2018: Molecular Partners reports key financials for H1 18 and corporate highlights for the second quarter 2018 20
Feb 08, 2018: Molecular Partners Reports Significant Progress of Pipeline and Preliminary Unaudited Key Financials for 2017 – Key Value Inflection Points in 2018 23
Aug 30, 2017: Molecular Partners reports key financials and corporate highlights for H1 2017: Pipeline development on track with several key milestones ahead 26
Feb 09, 2017: Molecular Partners reports preliminary unaudited key financials for 2016: Advancements across all therapeutic areas – Ongoing strong cash position 29
Corporate Communications 31
Jun 21, 2018: Molecular Partners Names Pamela A. Trail as Chief Scientific Officer; Michael T. Stumpp Assumes Role of Chief Operating Officer of the Company 31
May 12, 2017: Patrick Amstutz Appointed as Chief Executive Officer 32
May 11, 2017: Shareholders of Molecular Partners approved all Board proposals at the Annual General Meeting – Gwen Fyfe elected new Board member 33
Apr 12, 2017: Christian Zahnd appointed as Honorary Chairman of the Board of Directors as he decided not to stand for re-election as member of the Board of Directors at the Annual General Meeting 2017 34
Product News 35
11/09/2017: Molecular Partners Expands and Advances Robust Pipeline of DARPin Therapies in Oncology and Ophthalmology 35
Other Significant Developments 36
Apr 26, 2018: Further MP0250 clinical data and partner interest underline Molecular Partners’ continued progress of its proprietary oncology compounds 36
Oct 26, 2017: Molecular Partners: Interim Management Statement Q3 2017 39
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Molecular Partners AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Molecular Partners AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Molecular Partners AG, Deals By Therapy Area, 2012 to YTD 2018 8
Molecular Partners AG, Medical Devices Deals, 2012 to YTD 2018 9
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Molecular Partners and AstraZeneca Enter into Partnership 11
Molecular Partners Reinforces Partnership with Allergan 12
Allergan Exercises Option Agreement with Molecular Partners 13
Molecular Partners Raises USD31.7 Million in Private Placement of Shares 14
Molecular Partners Announces Partial Exercise of Underwriter’s Option for IPO for USD108 Million 15
Molecular Partners AG, Key Competitors 17
Molecular Partners AG, Key Employees 18

List of Figures
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Molecular Partners AG, Medical Devices Deals, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Molecular Partners AG (MOLN):製薬・医療:M&Aディール及び事業提携情報(Molecular Partners AG (MOLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆